報價延遲最少15分鐘:2025/06/04 12:35 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
36.65 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-5.83/-2.83
|
|
企業價值
3.47B
|
| 資產負債 |
|
每股賬面淨值
1.53
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
560.23M
|
|
每股收益
4.34
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/06/04 12:35 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. |